Frontier Science Scotland strengthens board of trustees with new appointment


FRONTIER Science Scotland (FSS), a leading contract clinical research organisation, advancing drug development by delivering excellence in clinical trials, announces the appointment of Professor Bjoern Schelter as a new Director to its Board of Trustees. Bjoern brings valuable strategic insights into the Company’s core capabilities across clinical trials including data management, biostatistical analysis and quality assurance.

Professor Bjoern Schelter is CEO of GT Diagnostics (UK) Ltd and Chief Analytics Officer of TauRx Therapeutics and is also affiliated with the University of Aberdeen as Professor for Applied Mathematics. With over 20 years’ experience in the health care sector, Bjoern has led research teams since 2006. The focus of his work is on developing data-science based technologies to advance the understanding of diseases and ultimately help patients around the world.

Professor Chris Robertson, of the Department of Mathematics and Statistics at the University of Strathclyde, Glasgow, and Chair of FSS’s Board of Trustees, added,

“I am delighted to welcome Bjoern to the FSS Board of Trustees. His extensive leadership experience in healthcare R&D, specifically in data-science based technologies and quality assurance in clinical trials, will be a source invaluable advice as FSS expands its service offering to global industry partners.”

Professor Bjoern Schelter commented on his appointment, “I am deeply interested in FSS and its outstanding services through a not-for-profit model. Therefore I am pleased to be part of the FSS Board. I look forward to assisting FSS to develop its services and grow as an organisation.”

The Latest Stories

Over 90% of Britons Worried About Digital Identity Theft
Half a Million Women Absent from the IT Sector
Banking complaints hit a 10-year high
Commercial landlord market study confirms that providing EV charging increases customer footfall, retains tenants and increases site dwell times